Home » Zogenix Scoops Up FDA Fast Track Status for ZX008
Zogenix Scoops Up FDA Fast Track Status for ZX008
The FDA has fast tracked Zogenix’s ZX008 to treat seizures associated with Dravet syndrome, a rare form of childhood epilepsy.
The designation qualifies Zogenix for more communication with the agency and a potentially quicker review and approval process. Zogenix notes that a second Phase 3 study of ZX008 will begin in Europe this quarter.
Upcoming Events
-
07May
-
14May
-
30May